project Feasibility of Targeting Intimal Hyperplasia and Vascular Calcification for the treatment of Coronary Artery Disease via the Inhibition of ADAMTS-7 with Precision-Directed Catalytic Cleft-Binding Antibodies.

This application is a 6 month collaborative project with VASGEN Ltd to develop and characterise prototype antibody inhibitors of the ADAMTS-7 protease. Vasgen will licence its antibody technology to UH to develop the antibodies and characterise them biochemically and functionally in vitro. the project could lead to further collaborative studies aimed to develop a therapeutic lead and clinical strategy.